Nicox S.A.
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
COX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013018124 (+6 more)
- LEI:
- 969500EZGEO9W4JXR353
- Country:
- France
- Address:
- SOPHIA, 06410 BIOT
- Website:
- https://www.nicox.com/
Description
Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-09-01 17:45 |
Number of voting rights as of August 31, 2022
|
English | 189.9 KB | ||
| 2022-09-01 17:45 |
Nombre de droits de vote au 31 août 2022
|
French | 189.4 KB | ||
| 2022-08-03 07:30 |
Nicox : Participation à des conférences financières et scientifiques au troisiè…
|
French | 337.2 KB | ||
| 2022-08-03 07:30 |
Nicox to Participate in Financial and Scientific Events in Q3 2022
|
English | 334.6 KB | ||
| 2022-08-01 17:45 |
NOMBRE D’ACTIONS COMPOSANT LE CAPITAL ET NOMBRE TOTAL DE DROITS DE VOTE AU 1ER …
|
French | 190.0 KB | ||
| 2022-08-01 17:45 |
NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND TOTAL NUMBER OF VOTING RIGHTS …
|
English | 190.2 KB | ||
| 2022-07-29 07:30 |
Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors
|
English | 326.0 KB | ||
| 2022-07-29 07:30 |
Nicox : Jean-François Labbé nommé Président du Conseil d’administration
|
French | 411.2 KB | ||
| 2022-07-20 07:30 |
Nicox : Résumé financier et point d’activité du deuxième trimestre 2022
|
French | 460.5 KB | ||
| 2022-07-20 07:30 |
Nicox Provides Second Quarter 2022 Financial and Business Highlights
|
English | 455.7 KB | ||
| 2022-07-08 07:30 |
Nicox: 2022 Extraordinary Shareholder Meeting
|
English | 249.5 KB | ||
| 2022-07-08 07:30 |
Nicox : Assemblée Générale Extraordinaire 2022
|
French | 323.0 KB | ||
| 2022-07-07 07:30 |
Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Oc…
|
English | 328.3 KB | ||
| 2022-07-07 07:30 |
Nicox : Publication de nouvelles données sur le NCX 470 montrant des améliorati…
|
French | 335.5 KB | ||
| 2022-07-05 07:30 |
Nicox : Bilan semestriel du contrat de liquidité de la société NICOX
|
French | 449.3 KB |
Automate Your Workflow. Get a real-time feed of all Nicox S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nicox S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nicox S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
